Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT00231166
- Locations
- 🇺🇸
St. Vincent's Comprehensive Cancer Center Dept. of St. Vincent's Cancer, New York, New York, United States
🇺🇸University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102, Philadelphia, Pennsylvania, United States
🇺🇸Fred Hutchinson Cancer Research Center Dept. of FHCRC, Seattle, Washington, United States
Long-term Study of Ciclosporin for Atopic Dermatitis
- Conditions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00232063
Verification Study of Ciclosporin for Atopic Dermatitis
- Conditions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00232076
Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 291
- Registration Number
- NCT00229138
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly
- First Posted Date
- 2005-09-26
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT00225979
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-05-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 460
- Registration Number
- NCT00219141
- Locations
- 🇦🇷
sites in Argentina, Argentina, Argentina
🇩🇪sites in Germany, Germany, Germany
🇪🇸sites in Spain, Spain, Spain
Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT00219297
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸University of California Davis Cancer Center UC Davis Cancer (3), Sacramento, California, United States
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00219271
- Locations
- 🇬🇷
Novartis Investigative Site, Athens, Greece
Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 359
- Registration Number
- NCT00219284
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 218
- Registration Number
- NCT00172055
- Locations
- 🇧🇪
Novaris Investigative Site, Libramont, Belgium
🇧🇪Novartis Investigative Site, Woluwe-Saint-Lambert, Belgium